196 related articles for article (PubMed ID: 17448964)
1. Disease relapse after haematopoietic stem cell transplantation: risk factors and treatment.
Dazzi F; Fozza C
Best Pract Res Clin Haematol; 2007 Jun; 20(2):311-27. PubMed ID: 17448964
[TBL] [Abstract][Full Text] [Related]
2. Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation.
Savani BN; Montero A; Kurlander R; Childs R; Hensel N; Barrett AJ
Bone Marrow Transplant; 2005 Dec; 36(11):1009-15. PubMed ID: 16205732
[TBL] [Abstract][Full Text] [Related]
3. Donor chimerism does not predict response to donor lymphocyte infusion for relapsed chronic myelogenous leukemia after allogeneic hematopoietic cell transplantation.
Chiorean EG; DeFor TE; Weisdorf DJ; Blazar BR; McGlave PB; Burns LJ; Brown C; Miller JS
Biol Blood Marrow Transplant; 2004 Mar; 10(3):171-7. PubMed ID: 14993882
[TBL] [Abstract][Full Text] [Related]
4. [Alloreactive donor lymphocytes (DLI) after allogeneic hematopoietic stem cell transplantation (HSCT): study of toxicity and efficacy].
Michallet AS; Nicolini F; Michallet M
Bull Cancer; 2003; 90(8-9):758-62. PubMed ID: 14609766
[TBL] [Abstract][Full Text] [Related]
5. [Second transplant from the same donor without conditioning for bone marrow aplasia after non-myeloablative hematopoietic stem cell transplantation for chronic myeloid leukemia].
Ishikawa I; Miyamura K; Yamada M; Sasaki O; Harigae H; Kameoka J; Meguro K; Sasaki T
Rinsho Ketsueki; 2005 Dec; 46(12):1288-92. PubMed ID: 16447801
[TBL] [Abstract][Full Text] [Related]
6. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
7. Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis.
Palandri F; Amabile M; Rosti G; Bandini G; Benedetti F; Usala E; Angelucci E; Tiribelli M; Fanin R; Martinelli G; Baccarani M
Bone Marrow Transplant; 2007 Feb; 39(3):189-91. PubMed ID: 17211436
[No Abstract] [Full Text] [Related]
8. Reduced-intensity conditioning followed by T-cell depleted allogeneic stem cell transplantation for patients with chronic myeloid leukaemia and minimal residual disease at the time of transplant: high risk of molecular relapse.
Ringhoffer M; Harsdorf Sv; Schmitt M; Wiesneth M; Zenz T; Stilgenbauer S; Greiner J; Döhner K; Marx M; Döhner H; Bunjes D
Br J Haematol; 2007 Jan; 136(1):127-30. PubMed ID: 17222200
[TBL] [Abstract][Full Text] [Related]
9. Association with the presence of naive T cells in chronic myeloid leukemia patients after allogeneic human stem cell transplantation and the lower incidence of chronic graft-versus host disease and relapse.
Wysoczanska B; Bogunia-Kubik K; Dlubek D; Jaskula E; Sok A; Drabczak-Skrzypek D; Sedzimirska M; Lange A
Transplant Proc; 2007 Nov; 39(9):2898-901. PubMed ID: 18022011
[TBL] [Abstract][Full Text] [Related]
10. Donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukaemia.
Gilleece MH; Dazzi F
Leuk Lymphoma; 2003 Jan; 44(1):23-8. PubMed ID: 12691139
[TBL] [Abstract][Full Text] [Related]
11. Resolution of sarcoidosis after allogeneic bone marrow transplantation with donor lymphocyte infusions.
Tauro S; Mahendra P
Bone Marrow Transplant; 2001 Apr; 27(7):757-9. PubMed ID: 11360118
[TBL] [Abstract][Full Text] [Related]
12. [Stem cell transplantation in the imatinib era].
Masszi T
Orv Hetil; 2005 May; 146(18 Suppl 1):900-4. PubMed ID: 15921302
[TBL] [Abstract][Full Text] [Related]
13. [Donor lymphocyte infusions as adoptive immunotherapy in patients with relapsed hematologic neoplasms post-allogenic transplant of hematopoietic progenitor cells].
Riera L; Koziner B
Medicina (B Aires); 2000; 60(2):259-69. PubMed ID: 10962823
[TBL] [Abstract][Full Text] [Related]
14. Late response to donor lymphocyte infusions in patients with chronic myeloid leukemia relapsing after allogeneic stem cell transplantation.
Gómez M; Urbano-Ispizua A; Cervantes F; Fernández-Avilés F; Rovira M; Carreras E
Haematologica; 2002 Sep; 87(9):1003-5. PubMed ID: 12217814
[TBL] [Abstract][Full Text] [Related]
15. Reduced-intensity conditioning for allogeneic stem cell transplantation in patients with chronic myeloid leukemia is associated with better overall survival but inferior disease-free survival when compared with myeloablative conditioning - a retrospective study of the Czech National Hematopoietic Stem Cell Transplantation Registry.
Faber E; Koza V; Vitek A; Mayer J; Sedlacek P; Zak P; Zapletalova J; Benesova K; Krejcova H; Steinerova K; Maresova I; Cetkovsky P;
Neoplasma; 2007; 54(5):443-6. PubMed ID: 17688375
[TBL] [Abstract][Full Text] [Related]
16. Late onset membranous nephropathy complicating donor lymphocyte infusion for leukaemia relapse after allogeneic stem cell transplantation.
Lam MF; Au WY; Tse KC; Chan TM; Chan GS; Chan KW; Lai KN
Am J Hematol; 2007 Apr; 82(4):327-8. PubMed ID: 17177190
[No Abstract] [Full Text] [Related]
17. Allogeneic stem cell transplantation for chronic myeloid leukemia.
Barrett J
Semin Hematol; 2003 Jan; 40(1):59-71. PubMed ID: 12563612
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia.
Elliott MA; Tefferi A; Hogan WJ; Letendre L; Gastineau DA; Ansell SM; Dispenzieri A; Gertz MA; Hayman SR; Inwards DJ; Lacy MQ; Micallef IN; Porrata LF; Litzow MR
Bone Marrow Transplant; 2006 Jun; 37(11):1003-8. PubMed ID: 16604096
[TBL] [Abstract][Full Text] [Related]
19. DLI or second transplant.
Greinix HT
Ann Hematol; 2002; 81 Suppl 2():S34-5. PubMed ID: 12611068
[TBL] [Abstract][Full Text] [Related]
20. Response to donor lymphocyte infusions for chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to maximize therapeutic efficacy.
Simula MP; Marktel S; Fozza C; Kaeda J; Szydlo RM; Nadal E; Bua M; Rahemtulla A; Kanfer E; Marin D; Olavarria E; Goldman JM; Apperley JF; Dazzi F
Leukemia; 2007 May; 21(5):943-8. PubMed ID: 17361226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
